Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu
Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu
复制标题
DOI：
10.1016/j.ijgo.2008.04.008
复制
发表时间：
2008-08-01
影响因子：
3.8
通讯作者：
Pecorelli, Sergio
中科院分区：
文献类型：
--
作者：
Santin, Alessandro D.;Bellone, Stefania;Pecorelli, Sergio
目的：研究曲妥珠单抗对免疫组织化学显示 HER2/neu 受体过表达的进展性或复发性转移性子宫内膜癌患者的影响。方法：对 2 名符合研究标准、通过荧光原位杂交进行 c-erbB2 基因扩增、并在放射治疗和/或挽救性化疗后接受曲妥珠单抗治疗的患者进行疾病进展检查。结果：通过连续 CT 扫描和血清 CA-125 评估，证实了两名患者对曲妥珠单抗单药或联合化疗的临床反应。这些患有进行性或复发性转移性疾病的患者症状得到缓解，生存期延长，且没有观察到明显的毒性。结论：对于过度表达 HER2/neu 的晚期、复发性和/或转移性子宫内膜癌患者，曲妥珠单抗作为单药或与化疗联合使用可能是一种可行的治疗选择。 (C) 2008 年国际妇产科联合会。由爱思唯尔爱尔兰有限公司出版。保留所有权利。
Objective: To study the effect of trastuzumab in patients with progressive or recurrent metastatic endometrial carcinoma shown by immunohistochemistry to overexpress the HER2/neu receptor. Methods: Disease progression was examined in 2 patients who met the study criteria, had c-erbB2 gene amplification by fluorescence in situ hybridization, and were treated with trastuzumab following radiation treatment and/or salvage chemotherapy. Results: The clinical responses to trastuzumab as a single agent or in combination with chemotherapy were confirmed in both patients by serial CT scans and serum CA-125 evaluations. These patients with progressive or recurrent metastatic disease experienced relief from their symptoms and prolonged survival with no significant toxicity observed. Conclusion: Trastuzumab may be a viable therapeutic option as single agent or in combination with chemotherapy in patients with advanced, recurrent, and/or metastatic endometrial carcinomas overexpressing HER2/neu. (C) 2008 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd. All rights reserved.